Needham & Company LLC reaffirmed their buy rating on shares of Enovis (NYSE:ENOV - Free Report) in a research note published on Wednesday,Benzinga reports. The firm currently has a $64.00 price target on the stock.
Enovis Stock Performance
Shares of Enovis stock traded down $0.12 on Wednesday, reaching $32.41. 1,260,523 shares of the stock were exchanged, compared to its average volume of 721,395. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $1.85 billion, a PE ratio of -14.80 and a beta of 1.86. Enovis has a 1-year low of $30.58 and a 1-year high of $62.79. The business has a fifty day moving average price of $40.90 and a two-hundred day moving average price of $43.09.
Enovis (NYSE:ENOV - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.92 by $0.06. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The business had revenue of $560.98 million during the quarter, compared to the consensus estimate of $555.14 million. As a group, research analysts anticipate that Enovis will post 2.79 earnings per share for the current fiscal year.
Institutional Trading of Enovis
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in Enovis by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 5,486,130 shares of the company's stock valued at $240,731,000 after buying an additional 75,348 shares in the last quarter. DAVENPORT & Co LLC increased its stake in Enovis by 6.0% in the 4th quarter. DAVENPORT & Co LLC now owns 2,782,341 shares of the company's stock valued at $121,181,000 after purchasing an additional 157,216 shares in the last quarter. Royce & Associates LP raised its holdings in Enovis by 2.8% during the fourth quarter. Royce & Associates LP now owns 2,470,576 shares of the company's stock worth $108,409,000 after purchasing an additional 66,891 shares during the last quarter. State Street Corp grew its holdings in Enovis by 4.3% in the third quarter. State Street Corp now owns 1,647,220 shares of the company's stock valued at $70,913,000 after purchasing an additional 68,190 shares during the last quarter. Finally, River Road Asset Management LLC increased its position in shares of Enovis by 3.8% in the fourth quarter. River Road Asset Management LLC now owns 1,238,357 shares of the company's stock valued at $54,339,000 after buying an additional 45,762 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company's stock.
About Enovis
(
Get Free Report)
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
See Also
Before you consider Enovis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enovis wasn't on the list.
While Enovis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
